Cyclin D1, EGFR, and Akt/mTOR pathway

详细信息    查看全文

• 作者：D. Dionysopoulos (1)
  K. Pavlakis (2)
  V. Kotoula (3) (4)
  E. Fountzilas (1)
  K. Markou (5)
  I. Karasmanis (6)
  N. Angouridakis (5)
  A. Nikolaou (6)
  K.T. Kalogeras (1)
  G. Fountzilas (1)
  
• 关键词：Epidermal growth factor receptor ; Akt ; mTOR ; Prognostic factors ; Laryngeal neoplasms ; EGFR ; Akt ; mTOR ; Prognostische Faktoren ; Larynxkarzinom
• 刊名：Strahlentherapie und Onkologie
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：189
• 期：3
• 页码：202-215
• 参考文献：1. Jemal A et al (2009) Cancer statistics. CA Cancer J Clin 59:225-49 CrossRef
  2. Ferlay J, Shin HR, Bray F et al (2010) GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 07 January 2013
  3. Duma MN, Kampfer S et al (2012) Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlenther Onkol 188:243-47 CrossRef
  4. Rades D, Meyners T et al (2011) Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. A matched-pair analysis. Strahlenther Onkol 187:541-47 CrossRef
  5. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359:1143-154 CrossRef
  6. Olthoff A, Ewen A et al (2009) Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer. Strahlenther Onkol 185:303-09 CrossRef
  7. Semrau S et al (2011) Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemo-radiotherapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol 187:15-2 CrossRef
  8. Selzer E, Liederer S et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187:373-77 CrossRef
  9. Maurer J, Hipp M et al (2011) Dysphagia, Impact on quality of life after radio(chemo)therapy of head and neck cancer. Strahlenther Onkol 187:744-49 CrossRef
  10. Rades D, Seibold ND et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626-32 CrossRef
  11. Mitsudomi T, Yatabe Y et al (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cencer. FEBS J 277:301-08 CrossRef
  12. Amornphimoltham P, Sriuranpong V et al (2004) Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10:4029-037 CrossRef
  13. Molinolo AA, Hewitt SM et al (2007) Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964-973 CrossRef
  14. Bellacosa A, Almadori G, Cavallo S et al (1996) Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 2:175-80
  15. Skarlos P et al (2012) Cancer Chemother Pharmacol 69:533-46
  16. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-072 CrossRef
  17. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head-and-neck cancer. N Engl J Med 345:1890-900 CrossRef
  18. Ha PK et al (2003) A transcriptional progression model for head and neck cancer. Clin Cancer Res 9:3058-064
  19. Freier K, Joos S et al (2003) Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 63:1179-182
  20. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20(Suppl 18):1s-3s
  21. Dassonville O, Formento JL et al (1993) Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11:1873-878
  22. Ang KK, Berkey BA (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-356
  23. Fountzilas E, Markou K et al (2012) Identification and validation of gene expression models that predict clinical outcome in patients with early laryngeal cancer. Ann Oncol 23:2146-153 CrossRef
  24. Pignataro L, Pruneri G, Carboni N et al (1998) Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 16:3069-077
  25. Rhodes A (2003) Quality assurance in immunohistochemistry. Am J Surg Pathol 27:1284-285 CrossRef
  26. Colombo N, McMeekin S et al (2007) A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol. (ASCO Ann Meet Proc 25:18S (abstract 5516))
  27. Witzig TE, Geyer SM et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-356 CrossRef
  28. Aguirre D, Boya P et al (2004) Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9:797-05 CrossRef
  29. Averous J et al (2008) Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27:1106-113 CrossRef
  30. Kong A, Leboucher P, Leek R et al (2006) Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res 66:2834-843 CrossRef
  31. Dei Tos AP, EIlis I et al (2005) Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41:1383-392 CrossRef
  32. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31-9 CrossRef
  33. Xia W, Lau YK et al (1999) Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-174
  34. Espina V et al (2009) Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl 3:874-82 CrossRef
  35. Espina V, Edmiston KH, Heiby M, Pierobon M et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7:1998-018 CrossRef
  36. Hennig G, Gehrmann M et al (2010) Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56:1845-853 CrossRef
  37. Zhang F, Wang ZM et al (2011) Application of RT-PCR in formalin-fixed and paraffin-embedded lung cancer tissues. Acta Pharmacol Sin 31:111-17 CrossRef
  
• 作者单位：D. Dionysopoulos (1)
  K. Pavlakis (2)
  V. Kotoula (3) (4)
  E. Fountzilas (1)
  K. Markou (5)
  I. Karasmanis (6)
  N. Angouridakis (5)
  A. Nikolaou (6)
  K.T. Kalogeras (1)
  G. Fountzilas (1)
  
  1. Department of Medical Oncology, “Papageorgiou-Hospital, Aristotle University of Thessaloniki School of Medicine, Peripheriaki odos, Nea Efkarpia, 56403, Thessaloniki, Greece
  2. Pathology Department, National & Kapodistrian University of Athens, Athens, Greece
  3. Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
  4. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
  5. First Department of Otorhinolaryngology, “AHEPA-Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
  6. ENT Department, “G. Papanikolaou-General Hospital, Thessaloniki, Greece
  
• ISSN：1439-099X

文摘

Introduction EGFR (epidermal growth factor receptor), cyclin D1 and Akt/mTOR pathways are active in head and neck cancer. The aim of this study was to explore biomarker expression, their correlations with clinicopathological parameters and their prognostic utility in a cohort of patients with localized squamous laryngeal carcinoma. Patients and methods We assessed relative messenger RNA expression of EGFR, Akt1, 2, and 3, mTOR and CCND1, copy number variants of the EGFR and CCND1 genes and immunohistochemical protein expression of EGFR, p-Akt308, p-Akt473, pmTOR, PTEN, p53 and cyclin D1 in paraffin-embedded tissue samples of localized laryngeal carcinomas. Results In 289?patients with T3- (77.8%), node-negative (84.1%) tumors of the larynx, high EGFR and CCND1 mRNA correlated with no or ex-smoking, (p--.003 and p--.029, respectively), while low Akt3 mRNA correlated with alcohol abuse, N0 stage, total laryngectomy, and absence of neck dissection. At a median follow-up of 74.5?months, high mTOR mRNA expression was marginally associated with shorter disease-free survival (hazard ratio [HR]--.54; p--.093) and high Akt3 mRNA with shorter overall survival (HR--.49; p--.0786), in univariate analysis. In multivariate analysis, node-positive status, subglottic–transglottic location, surgery other than total laryngectomy and mTOR/CCND1 mRNA interaction with a hazard ratio of 2.16 (p value for interaction: -.0010) were independent predictors of relapse, while node-positive status and subglottic–transglottic location were associated with higher risk for death. Conclusion In localized laryngeal cancer, clinicopathological parameters and an interaction of high mTOR and CCND1 mRNA expression were found to be associated with poor patient outcome.